DIANTHUS THERAPEUTICS
Live / Applied — Fifth extension granted (statement of use) (as of 12 Dec 2025)
What this means for you
Not registered yet, but its 31 May 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97436362
- Mark type
- Design + words
- Filed
- 31 May 2022
- Published for opposition
- 25 Apr 2023
- Attorney of record
- Jessica L. Rothstein
Goods and services
- Class 005 — Pharmaceuticals: monoclonal antibodies used in connection with complement therapies to treat autoimmune diseases
- Class 042 — Scientific and technological services: research and development services for the development of monoclonal antibodies used in connection with complement therapies to treat autoimmune diseases; clinical trials for others involving monoclonal antibodies used in connection with complement therapies to treat autoimmune diseases
Owner
- DIANTHUS THERAPEUTICS OPCO, INC., WALTHAM, MA, US
- Dianthus Therapeutics, Inc., Waltham, MA, US
- Dianthus Therapeutics, Inc., Waltham, MA, US
Prosecution history
- 12 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Dec 2025 — SOU EXTENSION 5 GRANTED
- 10 Dec 2025 — SOU EXTENSION 5 FILED
- 11 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 12 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 May 2025 — SOU EXTENSION 4 GRANTED
- 09 May 2025 — SOU EXTENSION 4 FILED
- 09 May 2025 — SOU TEAS EXTENSION RECEIVED
- 29 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Nov 2024 — SOU EXTENSION 3 GRANTED
- 07 Nov 2024 — SOU EXTENSION 3 FILED
- 27 Nov 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 07 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 21 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 May 2024 — SOU EXTENSION 2 GRANTED